In Vivo Emergence of Podovirus Resistance via

Jérémy Cherbuin, Jonathan Save, Emma Osswald, Grégory Resch

Abstract read

In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jérémy CherbuinLaboratory of Bacteriophages and Phage Therapy, Center for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP), Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID 0009-0007-1241-2693

Jonathan SaveLaboratory of Bacteriophages and Phage Therapy, Center for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP), Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID 0000-0003-4556-6756

Emma OsswaldLaboratory of Bacteriophages and Phage Therapy, Center for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP), Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID 0009-0007-9022-5527

Grégory ReschLaboratory of Bacteriophages and Phage Therapy, Center for Research and Innovation in Clinical Pharmaceutical Sciences (CRISP), Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID 0000-0003-2341-4591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phage therapy shows promise as an adjunct to antibiotics for treating Staphylococcus aureus infections. We previously reported a combined flucloxacillin/two-phage cocktail treatment selected for resistance to podovirus phage 66 in a rodent model of methicillin-susceptible

Indexed as

Anti-Bacterial AgentsEndocarditisEndocarditis, BacterialGlycosyltransferasesPhage TherapyPodoviridaeStaphylococcal InfectionsStaphylococcus aureusAnimalsDisease Models, AnimalMiceMutationStaphylococcus PhagesTeichoic AcidsAnti-Bacterial AgentsGlycosyltransferasesTeichoic Acidsbacteriophageexperimental infective endocarditisflucloxacillinphage-antibiotic synergismphage cocktailphage therapyStaphylococcus aureus

Identifiers

PMID40872753

DOI10.3390/v17081039

PMCPMC12390327

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.